Skip to main content
SpringerLink
Log in

Local Therapy Options for Oligometastatic Disease in the Liver

  • Colorectal Cancer Hepatic Metastases (MA Choti, Section Editor)
  • Published:
Current Colorectal Cancer Reports

Abstract

Our understanding of metastatic disease is constantly evolving. Survival outcomes for patients with colorectal cancer metastatic to the liver are poor, although a subset of patients with limited or “oligometastatic” disease may exist in a therapeutic window amenable to aggressive local intervention. The purpose of this review is to describe and compare the range of non-surgical local treatment options available for the treatment of oligometastatic colorectal disease involving the liver.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, et al. Metastatic patterns in adenocarcinoma. Cancer. 2006;106(7):1624–33. doi:10.1002/cncr.21778.

    Article  PubMed  Google Scholar 

  2. Leong SP, Nakakura EK, Pollock R, Choti MA, Morton DL, Henner WD, et al. Unique patterns of metastases in common and rare types of malignancy. J Surg Oncol. 2011;103(6):607–14. doi:10.1002/jso.21841.

    Article  PubMed  Google Scholar 

  3. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150(3):195–203. doi:10.1002/path.1711500308.

    Article  CAS  PubMed  Google Scholar 

  4. Kasper HU, Drebber U, Dries V, Dienes HP. Liver metastases: incidence and histogenesis. Z Gastroenterol. 2005;43(10):1149–57. doi:10.1055/s-2005-858576.

    Article  PubMed  Google Scholar 

  5. Geoghegan JG, Scheele J. Treatment of colorectal liver metastases. Br J Surg. 1999;86(2):158–69. doi:10.1046/j.1365-2168.1999.01013.x.

    Article  CAS  PubMed  Google Scholar 

  6. Leporrier J, Maurel J, Chiche L, Bara S, Segol P, Launoy G. A population-based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer. Br J Surg. 2006;93(4):465–74. doi:10.1002/bjs.5278.

    Article  CAS  PubMed  Google Scholar 

  7. Fong Y, Blumgart LH, Cohen AM. Surgical treatment of colorectal metastases to the liver. CA Cancer J Clin. 1995;45(1):50–62.

    Article  CAS  PubMed  Google Scholar 

  8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999;230(3):309–18. discussion 18–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Scheele J, Stang R, Altendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19(1):59–71.

    Article  CAS  PubMed  Google Scholar 

  10. Wei AC, Greig PD, Grant D, Taylor B, Langer B, Gallinger S. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol. 2006;13(5):668–76. doi:10.1245/ASO.2006.05.039.

    Article  PubMed  Google Scholar 

  11. Halsted WS. I. The results of radical operations for the cure of carcinoma of the breast. Ann Surg. 1907;46(1):1–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.

    CAS  PubMed  Google Scholar 

  13. Aloia TA, Vauthey JN, Loyer EM, Ribero D, Pawlik TM, Wei SH, et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg. 2006;141(5):460–6. doi:10.1001/archsurg.141.5.460. discussion 6–7.

    Article  PubMed  Google Scholar 

  14. Pastorino U, Buyse M, Friedel G, Ginsberg RJ, Girard P, Goldstraw P, Johnston M, McCormack P, Pass H, Putnam JB Jr; International Registry of Lung Metastases. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113(1):37–49.

  15. Shah SA, Haddad R, Al-Sukhni W, Kim RD, Greig PD, Grant DR, et al. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg. 2006;202(3):468–75. doi:10.1016/j.jamcollsurg.2005.11.008.

    Article  PubMed  Google Scholar 

  16. Weichselbaum RR, Hellman S. Oligometastases revisited. Nat Rev Clin Oncol. 2011;8(6):378–82. doi:10.1038/nrclinonc.2011.44.

    CAS  PubMed  Google Scholar 

  17. Palma DA, Salama JK, Lo SS, Senan S, Treasure T, Govindan R, et al. The oligometastatic state - separating truth from wishful thinking. Nat Rev Clin Oncol. 2014;11(9):549–57. doi:10.1038/nrclinonc.2014.96.

    Article  PubMed  Google Scholar 

  18. Badakhshi H, Grun A, Stromberger C, Budach V, Boehmer D. Oligometastases: the new paradigm and options for radiotherapy. A critical review. Strahlentherapie und Onkologie. 2013;189(5):357–62. doi:10.1007/s00066-013-0326-1.

    Article  CAS  PubMed  Google Scholar 

  19. Bradley CT, Strong VE. Surgical management of adrenal metastases. J Surg Oncol. 2014;109(1):31–5. doi:10.1002/jso.23461.

    Article  PubMed  Google Scholar 

  20. House MG, Ito H, Gonen M, Fong Y, Allen PJ, DeMatteo RP, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg. 2010;210(5):744–52. doi:10.1016/j.jamcollsurg.2009.12.040. 52–5.

    Article  PubMed  Google Scholar 

  21. Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer. 1997;80(8 Suppl):1529–37.

    Article  CAS  PubMed  Google Scholar 

  22. Norton L, Simon R. The Norton-Simon hypothesis revisited. Cancer Treat Rep. 1986;70(1):163–9.

    CAS  PubMed  Google Scholar 

  23. Simon R, Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol. 2006;3(8):406–7. doi:10.1038/ncponc0560.

    Article  PubMed  Google Scholar 

  24. Ahmed M, Solbiati L, Brace CL, Breen DJ, Callstrom MR, Charboneau JW, et al. Image-guided tumor ablation: standardization of terminology and reporting criteria-a 10-year update. Radiology. 2014;273(1):241–60. doi:10.1148/radiol.14132958.

    Article  PubMed  Google Scholar 

  25. Pua BB, Solomon SB. Ablative therapies in adrenal tumors: primary and metastatic. J Surg Oncol. 2012;106(5):626–31. doi:10.1002/jso.23191.

    Article  PubMed  Google Scholar 

  26. Pua BB, Thornton RH, Solomon SB. Ablation of pulmonary malignancy: current status. J Vasc Interv Radiol. 2010;21(8 Suppl):S223–32. doi:10.1016/j.jvir.2010.01.049.

    Article  PubMed  Google Scholar 

  27. Sotsky TK, Ravikumar TS. Cryotherapy in the treatment of liver metastases from colorectal cancer. Semin Oncol. 2002;29(2):183–91.

    Article  PubMed  Google Scholar 

  28. Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer. 2014;14(3):199–208. doi:10.1038/nrc3672.

    Article  CAS  PubMed  Google Scholar 

  29. Lu DS, Raman SS, Limanond P, Aziz D, Economou J, Busuttil R, et al. Influence of large peritumoral vessels on outcome of radiofrequency ablation of liver tumors. J Vasc Interv Radiol. 2003;14(10):1267–74.

    Article  PubMed  Google Scholar 

  30. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L. Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg. 2005;242(2):158–71.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Kuvshinoff BW, Ota DM. Radiofrequency ablation of liver tumors: influence of technique and tumor size. Surgery. 2002;132(4):605–11. discussion 11–2.

    Article  PubMed  Google Scholar 

  32. Rhim H, Goldberg SN, Dodd GD, 3rd, Solbiati L, Lim HK, Tonolini M et al. Essential techniques for successful radio-frequency thermal ablation of malignant hepatic tumors. Radiographics. 2001;21 Spec No:S17-35; discussion S6-9. doi:10.1148/radiographics.21.suppl_1.g01oc11s17.

  33. Wong SL, Mangu PB, Choti MA, Crocenzi TS, Dodd 3rd GD, Dorfman GS, et al. American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol. 2010;28(3):493–508. doi:10.1200/JCO.2009.23.4450.

    Article  PubMed  Google Scholar 

  34. Doyle MB, Chapman WC. Radiofrequency ablation for resectable colorectal hepatic metastases: is it time for a randomized controlled trial? Ann Surg. 2010;251(5):804–6. doi:10.1097/SLA.0b013e3181dbb1f8.

    Article  PubMed  Google Scholar 

  35. Lo SS, Fakiris AJ, Chang EL, Mayr NA, Wang JZ, Papiez L, et al. Stereotactic body radiation therapy: a novel treatment modality. Nat Rev Clin Oncol. 2010;7(1):44–54. doi:10.1038/nrclinonc.2009.188.

    Article  PubMed  Google Scholar 

  36. Iyengar P, Timmerman RD. Stereotactic ablative radiotherapy for non-small cell lung cancer: rationale and outcomes. J Natl Compr Cancer Netw. 2012;10(12):1514–20.

    Google Scholar 

  37. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303(11):1070–6. doi:10.1001/jama.2010.261.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, et al. Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys. 2014;88(4):892–8. doi:10.1016/j.ijrobp.2013.11.010.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Hasselle MD, Haraf DJ, Rusthoven KE, Golden DW, Salgia R, Villaflor VM, et al. Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol. 2012;7(2):376–81. doi:10.1097/JTO.0b013e31824166a5.

    Article  PubMed  Google Scholar 

  40. Kelsey CR, Salama JK. Stereotactic body radiation therapy for treatment of primary and metastatic pulmonary malignancies. Surg Oncol Clin N Am. 2013;22(3):463–81. doi:10.1016/j.soc.2013.02.011.

    Article  PubMed  Google Scholar 

  41. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878–86. doi:10.1016/j.ijrobp.2011.08.036. Results of patients with limited metastatic disease treated with SBRT with extended follow-up.

    Article  PubMed  Google Scholar 

  42. Milano MT, Philip A, Okunieff P. Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys. 2009;73(3):832–7. doi:10.1016/j.ijrobp.2008.04.073.

    Article  PubMed  Google Scholar 

  43. Rusthoven KE, Kavanagh BD, Burri SH, Chen C, Cardenes H, Chidel MA, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol. 2009;27(10):1579–84. doi:10.1200/JCO.2008.19.6386.

    Article  PubMed  Google Scholar 

  44. Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 2009;27(10):1572–8. doi:10.1200/JCO.2008.19.6329. Clinical trial evaluating 3-fraction SBRT for liver metastases.

    Article  PubMed  Google Scholar 

  45. Salama JK, Hasselle MD, Chmura SJ, Malik R, Mehta N, Yenice KM, et al. Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer. 2012;118(11):2962–70. doi:10.1002/cncr.26611.

    Article  PubMed  Google Scholar 

  46. Salama JK, Kirkpatrick JP, Yin FF. Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol. 2012;9(11):654–65. doi:10.1038/nrclinonc.2012.166.

    Article  CAS  PubMed  Google Scholar 

  47. Tree AC, Khoo VS, Eeles RA, Ahmed M, Dearnaley DP, Hawkins MA, et al. Stereotactic body radiotherapy for oligometastases. Lancet Oncol. 2013;14(1):e28–37. doi:10.1016/S1470-2045(12)70510-7.

    Article  PubMed  Google Scholar 

  48. Villaruz LC, Kubicek GJ, Socinski MA. Management of non-small cell lung cancer with oligometastasis. Curr Oncol Rep. 2012;14(4):333–41. doi:10.1007/s11912-012-0240-1.

    Article  PubMed  Google Scholar 

  49. Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn Jr PA, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7(12):1807–14. doi:10.1097/JTO.0b013e3182745948.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300(5622):1155–9. doi:10.1126/science.1082504.

    Article  CAS  PubMed  Google Scholar 

  51. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114(3):589–95. doi:10.1182/blood-2009-02-206870.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Ambrosino G, Polistina F, Costantin G, Francescon P, Guglielmi R, Zanco P, et al. Image-guided robotic stereotactic radiosurgery for unresectable liver metastases: preliminary results. Anticancer Res. 2009;29(8):3381–4.

    PubMed  Google Scholar 

  53. Hoyer M, Roed H, Traberg Hansen A, Ohlhuis L, Petersen J, Nellemann H, et al. Phase II study on stereotactic body radiotherapy of colorectal metastases. Acta Oncol. 2006;45(7):823–30. doi:10.1080/02841860600904854.

    Article  PubMed  Google Scholar 

  54. Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC, et al. Stereotactic body radiation therapy for primary and metastatic liver tumors: a single institution phase i-ii study. Acta Oncol. 2006;45(7):831–7. doi:10.1080/02841860600897934.

    Article  PubMed  Google Scholar 

  55. Rule W, Timmerman R, Tong L, Abdulrahman R, Meyer J, Boike T, et al. Phase I dose-escalation study of stereotactic body radiotherapy in patients with hepatic metastases. Ann Surg Oncol. 2011;18(4):1081–7. doi:10.1245/s10434-010-1405-5.

    Article  PubMed  Google Scholar 

  56. Scorsetti M, Comito T, Tozzi A, Navarria P, Fogliata A, Clerici E, et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol. 2015;141(3):543–53. doi:10.1007/s00432-014-1833-x.

    Article  CAS  PubMed  Google Scholar 

  57. Herfarth KK, Debus J, Wannenmacher M. Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial. Front Radiat Ther Oncol. 2004;38:100–5.

    Article  PubMed  Google Scholar 

  58. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78(2):486–93. doi:10.1016/j.ijrobp.2009.08.020.

    Article  PubMed  Google Scholar 

  59. Meyer JJ, Foster RD, Lev-Cohain N, Yokoo T, Dong Y, Schwarz RE, et al. A phase I dose-escalation trial of single-fraction stereotactic radiation therapy for liver metastases. Ann Surg Oncol. 2015. doi:10.1245/s10434-015-4579-z.

    Google Scholar 

  60. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21(1):109–22.

    Article  CAS  PubMed  Google Scholar 

  61. Pan CC, Kavanagh BD, Dawson LA, Li XA, Das SK, Miften M, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76(3 Suppl):S94–100. doi:10.1016/j.ijrobp.2009.06.092.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Nag S. High dose rate brachytherapy: its clinical applications and treatment guidelines. Technol Cancer Res Treat. 2004;3(3):269–87.

    Article  PubMed  Google Scholar 

  63. Dritschilo A, Grant EG, Harter KW, Holt RW, Rustgi SN, Rodgers JE. Interstitial radiation therapy for hepatic metastases: sonographic guidance for applicator placement. AJR Am J Roentgenol. 1986;147(2):275–8. doi:10.2214/ajr.147.2.275.

    Article  CAS  PubMed  Google Scholar 

  64. Ricke J, Wust P, Stohlmann A, Beck A, Cho CH, Pech M, et al. CT-guided interstitial brachytherapy of liver malignancies alone or in combination with thermal ablation: phase I-II results of a novel technique. Int J Radiat Oncol Biol Phys. 2004;58(5):1496–505. doi:10.1016/j.ijrobp.2003.09.024.

    Article  PubMed  Google Scholar 

  65. Ricke J, Wust P, Stohlmann A, Beck A, Cho CH, Pech M, et al. CT-guided brachytherapy. A novel percutaneous technique for interstitial ablation of liver metastases. Strahlentherapie und Onkologie. 2004;180(5):274–80. doi:10.1007/s00066-004-1179-4.

    Article  PubMed  Google Scholar 

  66. Ricke J, Wust P, Wieners G, Beck A, Cho CH, Seidensticker M, et al. Liver malignancies: CT-guided interstitial brachytherapy in patients with unfavorable lesions for thermal ablation. J Vasc Inter Radiol. 2004;15(11):1279–86. doi:10.1097/01.RVI.0000141343.43441.06.

    Article  Google Scholar 

  67. Ricke J, Mohnike K, Pech M, Seidensticker M, Ruhl R, Wieners G, et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 2010;78(2):479–85. doi:10.1016/j.ijrobp.2009.09.026.

    Article  PubMed  Google Scholar 

  68. Ricke J, Wust P. Computed tomography-guided brachytherapy for liver cancer. Semin Radiat Oncol. 2011;21(4):287–93. doi:10.1016/j.semradonc.2011.05.005.

    Article  PubMed  Google Scholar 

  69. Collettini F, Singh A, Schnapauff D, Powerski MJ, Denecke T, Wust P, et al. Computed-tomography-guided high-dose-rate brachytherapy (CT-HDRBT) ablation of metastases adjacent to the liver hilum. Eur J Radiol. 2013;82(10):e509–14. doi:10.1016/j.ejrad.2013.04.046. Recent study evaluating HDR brachytherapy for liver metastases.

    Article  PubMed  Google Scholar 

  70. Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol. 2014;5(3):178–89. doi:10.3978/j.issn.2078-6891.2014.037.

    PubMed  PubMed Central  Google Scholar 

  71. Petre EN, Sofocleous CT, Solomon SB. Ablative and catheter-directed therapies for colorectal liver and lung metastases. Hematol Oncol Clin North Am. 2015;29(1):117–33. doi:10.1016/j.hoc.2014.09.007.

    Article  PubMed  Google Scholar 

  72. Vente MA, Wondergem M, van der Tweel I, van den Bosch MA, Zonnenberg BA, Lam MG, et al. Yttrium-90 microsphere radioembolization for the treatment of liver malignancies: a structured meta-analysis. Eur Radiol. 2009;19(4):951–9. doi:10.1007/s00330-008-1211-7.

    Article  CAS  PubMed  Google Scholar 

  73. Ackerman NB, Lien WM, Kondi ES, Silverman NA. The blood supply of experimental liver metastases. I. The distribution of hepatic artery and portal vein blood to “small” and “large” tumors. Surgery. 1969;66(6):1067–72.

    CAS  PubMed  Google Scholar 

  74. Kennedy A, Nag S, Salem R, Murthy R, McEwan AJ, Nutting C, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68(1):13–23. doi:10.1016/j.ijrobp.2006.11.060.

    Article  PubMed  Google Scholar 

  75. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60(5):1552–63. doi:10.1016/j.ijrobp.2004.09.004.

    Article  CAS  PubMed  Google Scholar 

  76. Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating radioembolization ((90)Y microspheres) into current treatment options for liver tumors: introduction to the international working group report. Am J Clin Oncol. 2012;35(1):81–90. doi:10.1097/COC.0b013e3181ec60b8.

    Article  PubMed  Google Scholar 

  77. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12(12):1711–20.

    Article  CAS  PubMed  Google Scholar 

  78. Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol. 2009;6(12):687–97. doi:10.1038/nrclinonc.2009.165.

    Article  CAS  PubMed  Google Scholar 

  79. Van Hazel G, Blackwell A, Anderson J, Price D, Moroz P, Bower G, et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol. 2004;88(2):78–85. doi:10.1002/jso.20141.

    Article  PubMed  Google Scholar 

  80. Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman Jr DE, Loehr SP, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65(2):412–25. doi:10.1016/j.ijrobp.2005.12.051.

    Article  CAS  PubMed  Google Scholar 

  81. Kalva SP, Rana RS, Liu R, Rachamreddy N, Dave B, Sharma A, et al. Yttrium-90 radioembolization as salvage therapy for liver metastases from colorectal cancer. Am J Clin Oncol. 2014. doi:10.1097/COC.0000000000000151.

    PubMed  Google Scholar 

  82. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol. 2010;28(23):3687–94. doi:10.1200/JCO.2010.28.5643.

    Article  CAS  PubMed  Google Scholar 

  83. Kruskal JB, Hlatky L, Hahnfeldt P, Teramoto K, Stokes KR, Clouse ME. In vivo and in vitro analysis of the effectiveness of doxorubicin combined with temporary arterial occlusion in liver tumors. J Vasc Interv Radiol. 1993;4(6):741–7.

    Article  CAS  PubMed  Google Scholar 

  84. Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-Melman M, Chapman WC, et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol. 2005;16(12):1661–6. doi:10.1097/01.RVI.0000182160.26798.A2.

    Article  PubMed  Google Scholar 

  85. Fiorentini G, Aliberti C, Mulazzani L, Coschiera P, Catalano V, Rossi D, et al. Chemoembolization in colorectal liver metastases: the rebirth. Anticancer Res. 2014;34(2):575–84.

    CAS  PubMed  Google Scholar 

  86. Fiorentini G, Aliberti C, Tilli M, Mulazzani L, Graziano F, Giordani P, et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res. 2012;32(4):1387–95.

    CAS  PubMed  Google Scholar 

  87. Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA, et al. Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin. 2009;59(3):145–70. doi:10.3322/caac.20013.

    Article  PubMed  Google Scholar 

  88. Timmerman RD, Herman J, Cho LC. Emergence of stereotactic body radiation therapy and its impact on current and future clinical practice. J Clin Oncol. 2014. doi:10.1200/JCO.2014.55.4675.

    PubMed Central  Google Scholar 

  89. Salama JK, Milano MT. Radical irradiation of extracranial oligometastases. J Clin Oncol. 2014. doi:10.1200/JCO.2014.55.9567.

    PubMed  Google Scholar 

  90. Palma DA, Haasbeek CJ, Rodrigues GB, Dahele M, Lock M, Yaremko B, et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer. 2012;12:305. doi:10.1186/1471-2407-12-305.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Michael R. Folkert declares that he has no conflict of interest.

Jeffrey Meyer has received clinical research trial support from Peregrine Pharmaceuticals, Inc., compensation from UpToDate, Inc., and Osler Review for service as a consultant, and research support through grants from Cancer Prevention and Research Institute of Texas and the American Cancer Society.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, TX, USA

    Michael R. Folkert & Jeffrey Meyer

Authors
  1. Michael R. Folkert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jeffrey Meyer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey Meyer.

Additional information

This article is part of the Topical Collection on Colorectal Cancer Hepatic Metastases

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Folkert, M.R., Meyer, J. Local Therapy Options for Oligometastatic Disease in the Liver. Curr Colorectal Cancer Rep 11, 241–249 (2015). https://doi.org/10.1007/s11888-015-0279-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11888-015-0279-0

Keywords

Search

Navigation